© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 22, 1747-1752,
November 21, 2001
© 2001 Oxford University Press
REPORT |
Quantitation of GSTP1 Methylation in Non-neoplastic Prostatic Tissue and Organ-Confined Prostate Adenocarcinoma
Affiliations of authors: C. Jerónimo, H. Usadel, Department of Otolaryngology–Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, MD; R. Henrique (Unit of Molecular Pathology, Department of Pathology), Portugal; J. Oliveira, (Department of Urology), C. Lopes (Unit of Molecular Pathology-Department of Pathology), Instituto Português de Oncologia de Francisco Gentil-Centro Regional do Porto, Portugal; W. G. Nelson, Department of Urology; D. Sidransky, Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division and Department of Urology, The Johns Hopkins University School of Medicine.
Correspondence to: David Sidransky, M.D., The Johns Hopkins University School of Medicine, Division of Cancer Research, 818 Ross Research Bldg., 720 Rutland Ave., Baltimore, MD 21205–2196, (e-mail: dsidrans{at}jhmi.edu).
Background: Methylation of regulatory sequences near GSTP1, which encodes the 
class glutathione S-transferase, is the most common epigenetic alteration associated with prostate cancer. We determined whether the quantitation of GSTP1 methylation in histopathologically distinct prostate tissue samples could improve prostate cancer detection. Methods: We used a fluorogenic real-time methylation-specific polymerase chain reaction (MSP) assay to analyze cytidine methylation in the GSTP1 promoter in prostate tissue samples from 69 patients with early-stage prostatic adenocarcinoma (28 of whom also had prostatic intraepithelial neoplasia lesions) and 31 patients with benign prostatic hyperplasia. The relative level of methylated GSTP1 DNA in each sample was determined as the ratio of MSP-amplified GSTP1 to MYOD1, a reference gene. We also performed a prospective, blinded investigation to quantitate GSTP1 promoter methylation in sextant prostate biopsy specimens from 21 additional patients with elevated serum prostate-specific antigen levels, 11 of whom had histologically identified adenocarcinoma and 10 of whom had no morphologic evidence of adenocarcinoma. All data were analyzed by using nonparametric two-sided statistical tests. Results: The median ratios (and interquartile ranges) of MSP-amplified GSTP1 to MYOD1 in resected benign hyperplastic prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0 (range, 0–0.1), 1.4 (range, 0– 45.9), and 250.8 (range, 53.5–697.5), respectively; all of these values were statistically significantly different (P<.001). The median ratios of MSP-amplified GSTP1 to MYOD1 in the prospectively collected sextant biopsy samples were 410.6 for the patients with adenocarcinoma and 0.0 for the patients with no evidence of adenocarcinoma (P<.001). Conclusion: Quantitation of GSTP1 methylation accurately discriminates between normal hyperplastic tissue and prostatic carcinoma in small samples of prostate tissue and may augment the standard pathologic/histologic assessment of the prostate.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Troyer, M. S. Lucia, A. P. de Bruine, R. Mendez-Meza, M. M. Baldewijns, N. Dunscomb, M. Van Engeland, T. McAskill, K. Bierau, J. Louwagie, et al. Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2717 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Hoque, M. Prencipe, M. L. Poeta, R. Barbano, V. M. Valori, M. Copetti, A. P. Gallo, M. Brait, E. Maiello, A. Apicella, et al. Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2694 - 2700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Liu, J. K. Nagpal, W. Sun, J. Lee, M. S. Kim, K. L. Ostrow, S. Zhou, C. Jeronimo, R. Henrique, W. Van Criekinge, et al. ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer Clin. Cancer Res., June 15, 2008; 14(12): 3754 - 3760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Camoriano, S. R. Morey Kinney, M. T. Moser, B. A. Foster, J. L. Mohler, D. L. Trump, A. R. Karpf, and D. J. Smiraglia Phenotype-Specific CpG Island Methylation Events in a Murine Model of Prostate Cancer Cancer Res., June 1, 2008; 68(11): 4173 - 4182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Esteller Epigenetics in Cancer N. Engl. J. Med., March 13, 2008; 358(11): 1148 - 1159. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Carvalho, C. Jeronimo, M. M. Kim, R. Henrique, Z. Zhang, M. O. Hoque, S. Chang, M. Brait, C. S. Nayak, W.-W. Jiang, et al. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2008; 14(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Gustafson Locked Nucleic Acids Can Enhance the Analytical Performance of Quantitative Methylation-Specific Polymerase Chain Reaction J. Mol. Diagn., January 1, 2008; 10(1): 33 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Kim, K. Yamashita, Y. K. Chae, Y. Tokumaru, X. Chang, M. Zahurak, M. Osada, H. L. Park, A. Chuang, J. A. Califano, et al. A Promoter Methylation Pattern in the N-Methyl-D-Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., November 15, 2007; 13(22): 6658 - 6665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Henrique, F. R. Ribeiro, D. Fonseca, M. O. Hoque, A. L. Carvalho, V. L. Costa, M. Pinto, J. Oliveira, M. R. Teixeira, D. Sidransky, et al. High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients Clin. Cancer Res., October 15, 2007; 13(20): 6122 - 6129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roupret, V. Hupertan, D. R. Yates, J. W.F. Catto, I. Rehman, M. Meuth, S. Ricci, R. Lacave, G. Cancel-Tassin, A. de la Taille, et al. Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage Clin. Cancer Res., March 15, 2007; 13(6): 1720 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W.K. Chiu, S. S.C. Chim, I. H.N. Wong, C. S.C. Wong, W.-S. Lee, K. F. To, J. H.M. Tong, R. K.C. Yuen, A. S.W. Shum, J. K.C. Chan, et al. Hypermethylation of RASSF1A in Human and Rhesus Placentas Am. J. Pathol., March 1, 2007; 170(3): 941 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. U. Bai, A. Kaseb, S. Tejwani, G. W. Divine, E. R. Barrack, M. Menon, A. B. Pardee, and G. P.-V. Reddy Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine PNAS, February 13, 2007; 104(7): 2343 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gu, D. Berman, C. Lu, I. I. Wistuba, J. A. Roth, M. Frazier, M. R. Spitz, and X. Wu Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7329 - 7338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Urakami, H. Shiina, H. Enokida, H. Hirata, K. Kawamoto, T. Kawakami, N. Kikuno, Y. Tanaka, S. Majid, M. Nakagawa, et al. Wnt Antagonist Family Genes as Biomarkers for Diagnosis, Staging, and Prognosis of Renal Cell Carcinoma Using Tumor and Serum DNA Clin. Cancer Res., December 1, 2006; 12(23): 6989 - 6997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Foltz, G.-Y. Ryu, J.-G. Yoon, T. Nelson, J. Fahey, A. Frakes, H. Lee, L. Field, K. Zander, Z. Sibenaller, et al. Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. Cancer Res., July 1, 2006; 66(13): 6665 - 6674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Ribeiro, C. Jeronimo, R. Henrique, D. Fonseca, J. Oliveira, R. A. Lothe, and M. R. Teixeira 8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects. Clin. Cancer Res., July 1, 2006; 12(13): 3961 - 3970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, T. Kawasaki, M. Brahmandam, M. Cantor, G. J. Kirkner, D. Spiegelman, G. M. Makrigiorgos, D. J. Weisenberger, P. W. Laird, M. Loda, et al. Precision and Performance Characteristics of Bisulfite Conversion and Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis J. Mol. Diagn., May 1, 2006; 8(2): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Kim, K. Yamashita, J. H. Baek, H. L. Park, A. L. Carvalho, M. Osada, M. O. Hoque, S. Upadhyay, M. Mori, C. Moon, et al. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res., April 1, 2006; 66(7): 3409 - 3418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamashita, H. L. Park, M. S. Kim, M. Osada, Y. Tokumaru, H. Inoue, M. Mori, and D. Sidransky PGP9.5 Methylation in Diffuse-Type Gastric Cancer. Cancer Res., April 1, 2006; 66(7): 3921 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Vanaja, K. V. Ballman, B. W. Morlan, J. C. Cheville, R. M. Neumann, M. M. Lieber, D. J. Tindall, and C. Y.F. Young PDLIM4 Repression by Hypermethylation as a Potential Biomarker for Prostate Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1128 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Henrique, C. Jeronimo, M. R. Teixeira, M. O. Hoque, A. L. Carvalho, I. Pais, F. R. Ribeiro, J. Oliveira, C. Lopes, and D. Sidransky Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis Mol. Cancer Res., January 1, 2006; 4(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rosenbaum, M. O. Hoque, Y. Cohen, M. Zahurak, M. A. Eisenberger, J. I. Epstein, A. W. Partin, and D. Sidransky Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy Clin. Cancer Res., December 1, 2005; 11(23): 8321 - 8325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Teodoridis, J. Hall, S. Marsh, H. D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H. L. McLeod, G. Strathdee, et al. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer Cancer Res., October 1, 2005; 65(19): 8961 - 8967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Miyamoto and T. Ushijima Diagnostic and Therapeutic Applications of Epigenetics Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 293 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Mandelker, K. Yamashita, Y. Tokumaru, K. Mimori, D. L. Howard, Y. Tanaka, A. L. Carvalho, W.-W. Jiang, H. L. Park, M. S. Kim, et al. PGP9.5 Promoter Methylation Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma Cancer Res., June 1, 2005; 65(11): 4963 - 4968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Laird Cancer epigenetics Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Belinsky Emerging Role of Gene Promoter Hypermethylation in Population-Based Screening for Cancer Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 89 - 92. [Full Text] [PDF]
|
|
|
|
 |
|
 L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jeronimo, R. Henrique, M. O. Hoque, E. Mambo, F. R. Ribeiro, G. Varzim, J. Oliveira, M. R. Teixeira, C. Lopes, and D. Sidransky A Quantitative Promoter Methylation Profile of Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8472 - 8478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Gonzalgo, S. Yegnasubramanian, G. Yan, C. G. Rogers, T. L. Nicol, W. G. Nelson, and C. P. Pavlovich Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis Clin. Cancer Res., November 1, 2004; 10(21): 7276 - 7283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Enokida, H. Shiina, M. Igawa, T. Ogishima, T. Kawakami, W. W. Bassett, J. W. Anast, L.-C. Li, S. Urakami, M. Terashima, et al. CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer Cancer Res., September 1, 2004; 64(17): 5956 - 5962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alaminos, V. Davalos, N.-K. V. Cheung, W. L. Gerald, and M. Esteller Clustering of Gene Hypermethylation Associated With Clinical Risk Groups in Neuroblastoma J Natl Cancer Inst, August 18, 2004; 96(16): 1208 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Jeronimo, R Henrique, J Oliveira, F Lobo, I Pais, M R Teixeira, and C Lopes Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer J. Clin. Pathol., August 1, 2004; 57(8): 872 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Reesink-Peters, G. B. A. Wisman, C. Jeronimo, C. Y. Tokumaru, Y. Cohen, S. M. Dong, H. G. Klip, H. J. Buikema, A. J.H. Suurmeijer, H. Hollema, et al. Detecting Cervical Cancer by Quantitative Promoter Hypermethylation Assay on Cervical Scrapings: A Feasibility Study Mol. Cancer Res., May 1, 2004; 2(5): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yegnasubramanian, J. Kowalski, M. L. Gonzalgo, M. Zahurak, S. Piantadosi, P. C. Walsh, G. S. Bova, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer Cancer Res., March 15, 2004; 64(6): 1975 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Xing, Y. Cohen, E. Mambo, G. Tallini, R. Udelsman, P. W. Ladenson, and D. Sidransky Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis Cancer Res., March 1, 2004; 64(5): 1664 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Cottrell, J. Distler, N. S. Goodman, S. H. Mooney, A. Kluth, A. Olek, I. Schwope, R. Tetzner, H. Ziebarth, and K. Berlin A real-time PCR assay for DNA-methylation using methylation-specific blockers Nucleic Acids Res., January 13, 2004; 32(1): e10 - e10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kopelovich, J. A. Crowell, and J. R. Fay The Epigenome as a Target for Cancer Chemoprevention J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Herman and S. B. Baylin Gene Silencing in Cancer in Association with Promoter Hypermethylation N. Engl. J. Med., November 20, 2003; 349(21): 2042 - 2054. [Full Text] [PDF]
|
|
|
|
|
|
S. V. Harden, H. Sanderson, S. N. Goodman, A. A. W. Partin, P. C. Walsh, J. I. Epstein, and D. Sidransky Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies J Natl Cancer Inst, November 5, 2003; 95(21): 1634 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakayama, C. J. Bennett, J. L. Hicks, J. I. Epstein, E. A. Platz, W. G. Nelson, and A. M. De Marzo Hypermethylation of the Human Glutathione S-Transferase-{pi} Gene (GSTP1) CpG Island Is Present in a Subset of Proliferative Inflammatory Atrophy Lesions but Not in Normal or Hyperplastic Epithelium of the Prostate: A Detailed Study Using Laser-Capture Microdissection Am. J. Pathol., September 1, 2003; 163(3): 923 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.A. Schulz, M. Burchardt, and M.V. Cronauer Molecular biology of prostate cancer Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cohen, G. Singer, O. Lavie, S. M. Dong, U. Beller, and D. Sidransky The RASSF1A Tumor Suppressor Gene Is Commonly Inactivated in Adenocarcinoma of the Uterine Cervix Clin. Cancer Res., August 1, 2003; 9(8): 2981 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jeronimo, I. Costa, M. C. Martins, P. Monteiro, S. Lisboa, C. Palmeira, R. Henrique, M. R. Teixeira, and C. Lopes Detection of Gene Promoter Hypermethylation in Fine Needle Washings from Breast Lesions Clin. Cancer Res., August 1, 2003; 9(9): 3413 - 3417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Gonzalgo, C. P. Pavlovich, S. M. Lee, and W. G. Nelson Prostate Cancer Detection by GSTP1 Methylation Analysis of Postbiopsy Urine Specimens Clin. Cancer Res., July 1, 2003; 9(7): 2673 - 2677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Xing, Y. Tokumaru, G. Wu, W. B. Westra, P. W. Ladenson, and D. Sidransky Hypermethylation of the Pendred Syndrome Gene SLC26A4 Is an Early Event in Thyroid Tumorigenesis Cancer Res., May 1, 2003; 63(9): 2312 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Xing, H. Usadel, Y. Cohen, Y. Tokumaru, Z. Guo, W. B. Westra, B. C. Tong, G. Tallini, R. Udelsman, J. A. Califano, et al. Methylation of the Thyroid-stimulating Hormone Receptor Gene in Epithelial Thyroid Tumors: A Marker of Malignancy and a Cause of Gene Silencing Cancer Res., May 1, 2003; 63(9): 2316 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Harden, Y. Tokumaru, W. H. Westra, S. Goodman, S. A. Ahrendt, S. C. Yang, and D. Sidransky Gene Promoter Hypermethylation in Tumors and Lymph Nodes of Stage I Lung Cancer Patients Clin. Cancer Res., April 1, 2003; 9(4): 1370 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Jeronimo, R Henrique, P F Campos, J Oliveira, O L Caballero, C Lopes, and D Sidransky Endothelin B receptor gene hypermethylation in prostate adenocarcinoma J. Clin. Pathol., January 1, 2003; 56(1): 52 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kohen and A. Nyska Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification Toxicol Pathol, October 1, 2002; 30(6): 620 - 650. [Abstract] [PDF]
|
|
|
|
|
|
K. O. Toyooka, S. Toyooka, A. Maitra, Q. Feng, N. C. Kiviat, A. Smith, J. D. Minna, R. Ashfaq, and A. F. Gazdar Establishment and Validation of Real-Time Polymerase Chain Reaction Method for CDH1 Promoter Methylation Am. J. Pathol., August 1, 2002; 161(2): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jeronimo, G. Varzim, R. Henrique, J. Oliveira, M. J. Bento, C. Silva, C. Lopes, and D. Sidransky I105V Polymorphism and Promoter Methylation of the GSTP1 Gene in Prostate Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 445 - 450. [Abstract] [Full Text] [PDF]
|
|